Taiho Pharma ready to launch FGFR inhibitor Lytgobi in Japan

30 August 2023

Japanese drugmaker Taiho Pharmaceutical, a subsidiary of Otsuka Holdings (TYO: 4578), has announced that its FGFR inhibitor Lytgobi (futibatinib) has now been listed on the National Health Insurance (NHI) reimbursement price list, and the new product is scheduled for launch on September 7, 2023, in Japan.

Lytgobi, discovered by Taiho, binds covalently to FGFR 1, 2, 3 and 4, and inhibits FGFR-mediated signal transduction pathways selectively and irreversibly, resulting in reduced tumor cell proliferation and increased tumor cell death in tumors with FGFR1-4 genetic aberrations. Based on the results of the FOENIX-CCA2 Phase II trial, Lytgobi was approved in Japan in June 2023 for unresectable biliary tract cancer harboring FGFR2 gene fusions that has progressed after chemotherapy.

In September 2022, the US Food and Drug Administration (FDA) approved Lytgobi for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 gene fusions or other rearrangements.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK